Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cardiff Oncology Inc (CRDF)

10.12   -0.16 (-1.56%) 02-25 12:14
Open: 10.25 Pre. Close: 10.28
High: 10.45 Low: 9.86
Volume: 452,854 Market Cap: 357M
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.555 - 10.624 10.624 - 10.688
Low: 9.939 - 10.027 10.027 - 10.107
Close: 10.144 - 10.283 10.283 - 10.408

Technical analysis

as of: 2021-02-25 11:43:54 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.18     One year: 17.50
Support: Support1: 9.78    Support2: 8.14
Resistance: Resistance1: 12.99    Resistance2: 14.98
Pivot: 12.24
Moving Average: MA(5): 10.75     MA(20): 12.26
MA(100): 16.08     MA(250): 8.79
MACD: MACD(12,26): -1.07     Signal(9): -0.95
Stochastic oscillator: %K(14,3): 7.08     %D(3): 9.02
RSI: RSI(14): 32.98
52-week: High: 25.50  Low: 0.70  Change(%): 645.3
Average Vol(K): 3-Month: 193775  10-Days: 157457

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CRDF has closed above bottom band by 8.4%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 24 Feb 2021
Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference - Yahoo Finance

Thu, 18 Feb 2021
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Zacks.com

Thu, 11 Feb 2021
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule - Yahoo Finance

Sat, 06 Feb 2021
Cardiff Oncology, Inc. (NASDAQ:CRDF) Expected to Announce Quarterly Sales of $70,000.00 - MarketBeat

Tue, 02 Feb 2021
Cardiff Oncology Inc (CRDF) Stock: Buy, Hold, or Sell? - InvestorsObserver

Sun, 31 Jan 2021
Why Cardiff Oncology Ran Up 1,350% in 2020 - The Motley Fool

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35
Shares Float (M) 28
% Held by Insiders 0.24
% Held by Institutions 62.97
Shares Short (K) 5,850
Shares Short P. Month (K) 2,000

Stock Financials

EPS
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin -4974.21
Return on Assets (ttm) -41.1
Return on Equity (ttm) -84.4
Qtrly Rev. Growth 163.9
Gross Profit (p.s.) -0.309
Sales Per Share 0.010
EBITDA (p.s.) -0.465
Qtrly Earnings Growth
Operating Cash Flow (M) -14
Levered Free Cash Flow (M) -9

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 1062.80
Price to Cash Flow -24.92

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.